Fungal keratitis is an important cause of ocular morbidity
|
|
- Gervais Hines
- 5 years ago
- Views:
Transcription
1 Cornea Polyhexamethylene Biguanide and Calcineurin Inhibitors as Novel Antifungal Treatments for Aspergillus Keratitis Rachelle A. Rebong, 1 Ricardo M. Santaella, 1 Brian E. Goldhagen, 1 Christopher P. Majka, 1 John R. Perfect, 2 William J. Steinbach, 2 and Natalie A. Afshari 1 PURPOSE. To establish polyhexamethylene biguanide (PHMB) as an effective treatment for Aspergillus keratitis in a novel murine model. To determine the ability of the calcineurin inhibitors tacrolimus (FK506) and cyclosporine A (CSA) to enhance the activity of PHMB, amphotericin B (AMB), and voriconazole (VCZ) against Aspergillus keratitis. METHODS. In vitro studies: Broth antifungal susceptibility tests were performed with PHMB, AMB, VCZ, and FK506, individually and in combination against Aspergillus fumigatus. Minimum inhibitory concentrations (MIC) and fractional inhibitory concentration index (FICI) values were used to analyze antifungal activity. In vivo studies: A novel murine model was created to establish Aspergillus keratitis. Infected mice were randomly assigned to treatment groups receiving saline, CSA, AMB, VCZ, PHMB, AMB CSA, VCZ CSA, or PHMB CSA. An ophthalmologist blinded to the treatment groups assessed disease severity daily based on a grading scale. The mean end change in disease score was compared between groups. RESULTS. In vitro studies: FK506 in combination with PHMB, VCZ, or AMB enhanced fungal growth inhibition. FICI values showed an additive effect between FK506 and PHMB, AMB, or VCZ. PHMB monotherapy eliminated Aspergillus growth starting at 4 g/ml. In vivo studies: All treatment groups showed a significant improvement in disease score compared to the control group. CSA significantly worsened VCZ activity against Aspergillus keratitis. CONCLUSIONS. PHMB is an effective inhibitor of Aspergillus growth. Further investigation of the role of calcineurin inhibitors in the treatment for Aspergillus keratitis is warranted. (Invest Ophthalmol Vis Sci. 2011;52: ) DOI: / iovs Fungal keratitis is an important cause of ocular morbidity worldwide, leading to corneal ulceration and scarring, corneal transplantation, and blindness. 1,2 Whereas yeastlike Candida species predominate in more temperate climates, in tropical and subtropical areas such as Asia, Africa, and the southern From the 1 Duke University Eye Center and the 2 Division of Infectious Diseases, Duke University Medical Center, Durham, North Carolina. Supported by an Allergan Horizon Grant and Research to Prevent Blindness. Submitted for publication April 14, 2011; revised June 24, 2011; accepted July 17, Disclosure: R.A. Rebong, None; R.M. Santaella, None; B.E. Goldhagen, None; C.P. Majka, None; J.R. Perfect, None; W.J. Steinbach, None; N.A. Afshari, None Corresponding author: Natalie A. Afshari, Cornea and Refractive Surgery Service, Duke University Eye Center, DUMC Box 3802, Durham, NC 27710; natalie.afshari@duke.edu. United States, filamentous fungi such as Aspergillus species are the most common causes of fungal keratitis. 3 7 Currently available medical treatments for Aspergillus keratitis are not only largely ineffective but are also expensive. As the fungus penetrates deeper into the cornea, it becomes more difficult for the currently available treatments to reach and eradicate it. Although 15% to 27% of all patients with fungal keratitis ultimately require surgical intervention, Aspergillus species cause a particularly severe keratitis that necessitates keratoplasty in 42% to 60% of cases. 8 Given the prevalence of Aspergillus keratitis in many areas, particularly agricultural areas in developing nations, the development of new treatment options to increase effectiveness and to decrease cost is imperative. Despite the high incidence of keratomycoses globally, firstline topical polyene antifungal antibiotics, including amphotericin B (AMB) and natamycin, are not effective in completely eliminating severe keratomycoses. 7 Polyene macrolides work by binding to ergosterol, a sterol unique to fungal cell membranes, to form pores that allow the leakage of electrolytes and lead to cell death. 9 Natamycin is the only U.S. Food and Drug Administration (FDA) approved topical ocular antifungal, but it has poor corneal penetration, is cost-prohibitive, degrades easily, and is not commercially available in many regions of the world. 8,10 AMB is easier to handle and has been used to treat keratomycoses since 1959; however, it is not available as an ophthalmic preparation and needs to be compounded as a topical solution (0.15% 0.30%). 8,11 Topical AMB appears to be well tolerated at lower concentrations but causes conjunctival irritation at higher concentrations ( 0.50%), limiting its use at these concentrations. 2 Azoles are another class of antifungals used in the treatment of Aspergillus keratitis. They inhibit the cytochrome P-450 enzyme 14 -demethylase needed to convert lanosterol to ergosterol and lead to increased permeability of fungal cell membranes. 12 Voriconazole (VCZ) is a triazole antifungal agent with a broad spectrum of activity against Aspergillus species and is FDA-approved for the treatment of invasive aspergillosis. 10 The use of oral and topical VCZ, compounded as a 1% solution, has been reported in cases of fungal keratitis It has been effective in treating even Aspergillus infections resistant to AMB and has less severe side effects than AMB. Adverse effects of systemic VCZ include skin rashes and visual disturbances, which are usually mild and transient. 10 Elevation of hepatic enzymes rarely occurs. 12 However, VCZ is very costly and is not readily available in most parts of the world; like AMB, it must be compounded for use as an ophthalmic solution. Moreover, Aspergillus resistance to VCZ is a growing problem Polyhexamethylene biguanide (PHMB) is an inexpensive, readily available general biocide used as a swimming pool and contact lens disinfectant. 19 It is thought to work by disrupting the cell Investigative Ophthalmology & Visual Science, September 2011, Vol. 52, No. 10 Copyright 2011 The Association for Research in Vision and Ophthalmology, Inc. 7309
2 7310 Rebong et al. IOVS, September 2011, Vol. 52, No. 10 membranes of microorganisms, causing leakage of intracellular components and inhibiting the function of respiratory enzymes. 2 In vitro studies demonstrated PHMB s activity against Candida albicans, Fusarium solani, and Aspergillus niger. 19 In a rabbit model of Fusarium keratitis, 0.02% topical PHMB significantly reduced fungal growth compared to placebo. 20 Topical PHMB at concentrations of 0.02% to 0.053% has been used in the treatment of Acanthamoeba keratitis, but only one published animal study and no human studies have evaluated the use of PHMB against Aspergillus keratitis. 21 In the study evaluating PHMB treatment for Aspergillus keratitis, topical PHMB 0.02% was shown to be moderately effective against the infection in a rabbit model, showing significantly improved ulcer healing time compared with the control. 21 However, only six animals were treated in that study. Given the limited effectiveness, growing fungal resistance, and high cost associated with current treatment options for Aspergillus keratitis, the development of new treatments becomes important. Tacrolimus (FK506) and cyclosporine A (CSA) are immunosuppressive agents that target the calcineurin pathway to prevent rejection after organ transplantation. 22 Calcineurin is a serinethreonine phosphatase in the calcium signaling pathway of the conserved cell stress response. In fungi, this signaling pathway has been found to mediate growth, morphology, stress responses, and pathogenicity; it has also been shown to have a role in regulating cell wall formation. 23 Thus, calcineurin inhibitors may play a role not only in immunosuppression but also in inhibiting fungal growth. Evidence to support this hypothesis comes from previous studies which showed that calcineurin inhibitors inhibit the growth of A. fumigatus and that deletion of a gene within the calcineurin pathway of A. fumigatus reduces hyphal growth and attenuates virulence In addition, in a murine model of C. albicans keratitis, we have shown that calcineurin promotes corneal fungal infection and that calcineurin inhibitors can work synergistically with fluconazole in the treatment of Candida keratitis. 27 In fact, calcineurin inhibitors have already been shown to enhance the activity of caspofungin, an echinocandin that inhibits fungal cell wall synthesis, against Aspergillus species. 28 Our hypothesis is that similar synergy occurs between the calcineurin inhibitor FK506 and PHMB, AMB, and VCZ, respectively, against A. fumigatus. Using calcineurin inhibitors in combination with more conventional antifungals may provide a more effective and ultimately less costly treatment option for Aspergillus keratitis. METHODS Aspergillus Strain, Media, and Inoculum Preparation Wild-type A. fumigatus strain AF293 was used in all experiments. RPMI 1640, prepared according to CLSI (Clinical and Laboratory Standards Institute) standards, was used in all in vitro assays. 29 The inoculum was prepared from AF293 grown and harvested according to CLSI guideline for antifungal susceptibility testing. 29 Drug Preparation For in vitro assays, VCZ (Vfend; Pfizer, New York, NY) and AMB (Fungizone; Bristol-Myers Squibb, New York, NY) were prepared from powders according to CLSI guidelines. 29 FK506 was obtained from Astellas Pharma US, Inc. (Deerfield, IL). Polyhexamylene biguanide was obtained as a 0.02% ophthalmic solution from the Duke Pharmacy Compounding Facility (Durham, NC). It was prepared by adding 0.1 ml of a commercially available 20% PHMB solution (Baquacil; Arch Chemicals, Inc., Norwalk, CT) to 100 ml of normal saline. CSA was obtained as a 2% ophthalmic solution from the Duke Pharmacy Compounding Facility (Durham, NC). CSA was prepared by adding 0.6 ml of cyclosporine 100 mg/ml to 2.4 ml of corn oil. In Vitro Study Design Broth susceptibility testing of A. fumigatus was performed using FK506, PHMB, AMB, and VCZ individually and in combination (FK506 with PHMB, AMB, or VCZ) against wild-type A. fumigatus, according to a modified version of the CLSI guidelines. 29 A checkerboard titration was used, testing two drugs to compare the effects of the drugs alone and in combination. FK506 was used at concentrations between 0.01 and 0.08 g/ml, PHMB between 0.3 and 30 g/ml, AMB between 2 and 64 g/ml, and VCZ between and 1 g/ml. Samples were incubated for 48 hours at 37 C. At 48 hours, fungal growth was compared against that in the controls and across the various drug concentrations and combinations. Elimination of growth (MIC) and inhibition of growth, seen as the blunting of hyphal tips compared to control wells and known as the minimum inhibitory concentration (MIC), were assessed (Fig. 1). Quantitative Analysis of In Vitro Data The MIC and fractional inhibitory concentration index (FICI) were used to analyze in vitro antifungal activity and interactions against A. FIGURE 1. Examples of morphologic changes in wild-type A. fumigatus as seen in vitro. (A) Growth of untreated wild-type A. fumigatus. Note the extensively branching filaments. (B) Inhibition of growth with VCZ (0.25 g/ ml) and FK506 (40 ng/ml). (C) Inhibition of growth with PHMB (0.03 g/ml) and FK506 (2.25 g/ml). Note the blunted hyphal tips in (B) and (C) (arrows). (D) Elimination of growth with PHMB (3 g/ml). VCZ, voriconazole; FK506, tacrolimus; PHMB, polyhexamethylene biguanide. Bar, 200 m.
3 IOVS, September 2011, Vol. 52, No. 10 Novel Treatments for Aspergillus Keratitis 7311 fumigatus. The FICI is used to analyze drug interactions in combination and is calculated with the following formula: FICI [(MIC A in combination)/mic A] [MIC B in combination)/mic B]. Interpretation of the FICI can vary. In our study, interpretation was determined according to accepted standards by the following: FICI 0.5, synergistic effect; 0.5 but 1, additive effect; 1 but 4, indifferent effect; and 4, antagonistic effect. 30 In Vivo Study Design. A prospective randomized control study was performed according to a modified version of a previous protocol. 27 This protocol was approved by the Duke Institutional Animal Care and Use Committee. All study animals were treated according to the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research. A total of 158 adult male BALB/c mice, each weighing 20 to 25 g, were immunosuppressed with methylprednisolone (100 mg/kg) on days 5, 1, and 1 of inoculation, to rapidly establish infection. An intramuscular injection of a ketamine (10 mg/ml)-xylazine (1 mg/ml) mixture and a drop ( 30 L) of proparacaine 0.5% ophthalmic solution (Alcon, Fort Worth, TX) on the cornea were given for anesthesia. A drop of moxifloxacin 0.5% ophthalmic solution (Vigamox; Alcon) was then administered to the cornea to avoid bacterial contamination. The right corneas of 158 mice were de-epithelialized with a 30-gauge needle. Two 5- L suspensions, each containing 10 6 A. fumigatus spores, were evenly distributed in succession on the scratched cornea of each mouse. A previously described disease grading scale from 0 (no disease) to 4 (severe disease) was modified, and animals were graded as follows by an ophthalmologist who was blinded to the drug treatments (Fig. 2): 0, no sign of epithelial defect or infection; 1, signs of epithelial scratches but no infiltrate; 2, corneal infiltrate covering 25% to 50% of the corneal surface; 3, corneal infiltrate covering 50% to 75% of the corneal surface; and 4, corneal infiltrate covering 75% of the corneal surface. 27 Eyes that perforated received an automatic score of 4. Mice that developed clinically significant infection, indicated by reaching a grade of 2, were included in the study and started on antifungal treatment. Eligible mice were randomly assigned to one of eight treatment groups: balanced salt solution (control; Akorn, Lake Forest, IL), CSA, AMB, VCZ, PHMB, AMB CSA, VCZ CSA, or PHMB CSA. Study mice received four doses (5 L/dose) of the treatment drug each day for 10 consecutive days. For combination therapy, the drugs were administered in succession with at least 2 minutes between doses. Grading was performed daily with an operating microscope (Carl Zeiss Meditec, Dublin, CA). The results from two independent experiments were combined and analyzed. Statistical Analysis of In Vivo Data The mean changes in disease score between groups were compared using ANOVA, in which all pairwise comparisons between the eight groups were performed by using Student s t-test. We included all mice that developed a disease score of 2 and excluded mice that progressed to perforation of the cornea before treatment could be initiated. Data from mice whose corneas perforated after treatment was initiated were included (statistical analyses by JMP 8 software; SAS Institute, Cary, NC). RESULTS FK506 Enhanced PHMB, AMB, and VCZ Activity against A. fumigatus In Vitro With FK506 alone, inhibition of A. fumigatus growth occurred starting at 0.02 g/ml; fungal growth elimination did not occur, even at the highest concentration (Fig. 3). When FK506 was added to PHMB, AMB, or VCZ, fungal growth inhibition was enhanced and/or occurred at lower concentrations than when PHMB, AMB, or VCZ was used individually. PHMB eliminated growth starting at 4 g/ml but showed no effects at lower concentrations. With the addition of at least 0.01 g/ml FK506, PHMB still eliminated growth at 4 g/ml but also inhibited fungal growth at 0.5 g/ml PHMB (Fig. 3). AMB inhibited growth at the highest concentration 64 g/ml. With the addition of 0.08 g/ml FK506, fungal growth inhibition occurred at 8 g/ml AMB (Fig. 3). VCZ alone inhibited growth starting at 0.25 g/ml and eliminated growth starting at 1 g/ml. Fungal growth inhibition was enhanced at 0.25 g/ml VCZ with the addition of at least 0.02 g/ml FK506 (Fig. 3). FICI values indicated an in vitro additive effect when FK506 was combined with any of the study medications. The FICI values calculated from the individual and combined MICs of the drugs are 0.625, 0.625, and 1 for PHMB FK506, AMB FK506, and VCZ FK506, respectively (Table 1). All Murine Model Treatment Groups Showed Significant Improvement in Disease Score Compared to the Control Group A total of 103 of 158 mice achieved grade 2 infection and were included in the study, with 12 to 14 mice per group. The control group showed an increase or worsening of disease score after 10 days of treatment ( ). All FIGURE 2. Disease grading scale for evaluating mice corneas. The right eyes of BALB/c mice were scraped and inoculated with wild-type A. fumigatus. Study eyes were viewed and digitally photographed through an operating microscope. (A) A score of 0 indicated no sign of epithelial defect or infection. (B) A score of 1 showed signs of epithelial scratches but no infiltrate. (C) A score of 2 showed a corneal infiltrate covering 25% to 50% of the corneal surface. (D) A score of three showed a corneal infiltrate covering 50% to 75% of the corneal surface. (E) A score of 4 showed a corneal infiltrate covering 75% of the corneal surface or any signs of perforation, as shown in this image.
4 7312 Rebong et al. IOVS, September 2011, Vol. 52, No. 10 FIGURE 3. In vitro growth of A. fumigatus after treatment with FK506. In vitro growth inhibition occurred at lower concentrations of PHMB with the addition of FK506 and was enhanced at 0.25 g/ml VCZ with the addition of at least 0.02 g/ml FK506. In vitro growth of A. fumigatus after treatment with increasing doses of (A) 0.01, (B) 0.04 g/ml FK506 alone. Inhibition occurred at lower concentrations of PHMB and AMB, with the addition of FK506; (C) 0.5 g/ml PHMB 0.01 g/ml FK506. Note the increased area of clearing (arrow); (D) 0.5 g/ml PHMB 0.02 g/ml FK506; (E) 16 g/ml AMB 0.08 g/ml FK506; and (F) 64 g/ml AMB 0.08 g/ml FK506. In vitro growth inhibition was enhanced at 0.25 g/ml VCZ with the addition of at least 0.02 g/ml FK506; (G) 0.25 g/ml VCZ alone; and (H) 0.25 g/ml VCZ 0.08 g/ml FK506. Bar, 200 m. other treatment groups showed an improvement in disease score after 10 days of treatment, which can be seen as a decrease in the average daily disease score per group over TABLE 1. In Vitro Additive Effects of FK506 and Antifungals against Wild-Type A. fumigatus by Microdilution Checkerboard Interaction Drug MIC ( g/ml) MICs of Antifungal Agent Combination Drug A/FK506 ( g/ml) FICI FK AMB / VCZ / PHMB / FICI is used to analyze drug interactions in combination. FICI [(MIC A in combination)/mic A] [(MIC B in combination)/mic B]. FICI values were interpreted as follows: 0.5, synergistic effect; 0.5 but 1, additive effect; 1 but 4, indifferent effect; and 4, antagonistic effect. the complete course of treatment (Fig. 4) or calculated as a negative mean end change in disease score (Table 2). Of the treatment groups, AMB alone led to the largest mean end decrease in disease score from baseline ( ), whereas VCZ CSA led to the smallest mean end decrease in disease score from baseline ( ). P values for the comparison of the mean end change in disease score between the control group and the other study groups were all significant (P 0.05; Table 3). CSA significantly worsened VCZ activity against A. fumigatus infection in study mice. Significant differences were found between VCZ CSA and VCZ alone, AMB alone, and PHMB CSA (P , , and , respectively) in study mice. Mice receiving VCZ CSA showed significantly less improvement in disease score than did the mice receiving VCZ alone, AMB alone, or PHMB CSA. The rest of the comparisons between noncontrol treatment groups were not significant (Table 3).
5 IOVS, September 2011, Vol. 52, No. 10 Novel Treatments for Aspergillus Keratitis 7313 FIGURE 4. Mean daily disease scores over 10 days of treatment of the study mice. The control group showed an increase or worsening of mean daily disease score, whereas all other groups showed a decrease or improvement of mean daily disease score over the treatment course. BSS, balanced salt solution. Alopecia Was a Notable Side Effect in Study Mice All animals treated with CSA, either alone or in combination, developed alopecia around the treated eye (Fig. 5). DISCUSSION In this study, we sought to determine whether PHMB monotherapy is a viable treatment for Aspergillus keratitis and to ascertain the ability of calcineurin inhibitors to enhance the antifungal activity of PHMB, AMB, and VCZ against A. fumigatus, with the ultimate goal of providing better and less expensive treatment options for Aspergillus keratitis. To test our hypotheses, we developed a novel murine model for Aspergillus keratitis. In addition to establishing the efficacy of using calcineurin inhibitors for Aspergillus keratitis, our studies provided additional evidence to demonstrate the effectiveness of PHMB against Aspergillus. Each of the drugs tested showed antifungal activity individually against A. fumigatus. This result was expected for AMB and VCZ; even the calcineurin inhibitor FK506 had been shown in previous studies to have an effect against A. fumigatus. 24 However, data on PHMB s effectiveness against A. fumigatus were limited to a single study in a rabbit model, showing that PHMB was moderately effective but not better than natamycin in clearing Aspergillus keratitis. 21 In our study, PHMB was effective, not only in inhibiting but also in eliminating Aspergillus growth. Interestingly, unlike the other drugs tested, PHMB did not show a progression of fungal growth inhibition with increasing doses of the drug; rather, the transition between dilutions abruptly changed from no effect to complete elimination of fungal growth. Further in vitro and in vivo studies are warranted to determine PHMB s activity against Aspergillus. If shown to be effective, PHMB essentially, diluted pool cleaner could become a revolutionary and very affordable option for the treatment of Aspergillus keratitis for patients in agricultural areas of developing countries, where it is a significant problem. TABLE 2. Sample Size and Mean End Change in Disease Score after 10 Days of Treatment of Study Mice Treatment Group Sample Size End Change (Mean SD) Balanced salt solution (control) CSA AMB AMB CSA VCZ VCZ CSA PHMB PHMB CSA Based on our initial in vitro studies, FICI values indicate that the calcineurin inhibitor FK506 displays additive effects when combined with PHMB, AMB, or VCZ against A. fumigatus. An additive, as opposed to a synergistic, effect observed between these drugs may be explained in several ways. First, compared with Candida, against which CSA and fluconazole appear to show in vivo synergy, Aspergillus causes a more virulent corneal infection. 27 In Candida keratitis, even deep corneal lesions treated with medical therapy alone generally carry a favorable prognosis; in Aspergillus keratitis, deep corneal lesions generally do not respond to medical therapy and require surgical intervention. 2 The role of the calcineurin pathway may differ between Candida and Aspergillus species. More information on calcineurin-dependent genes in Candida species versus in Aspergillus species are available and differences between the two TABLE 3. Comparison of the Mean Changes in Disease Score between Two Groups of Study Mice Group A Group B P Balanced salt solution CSA < Balanced salt solution AMB < Balanced salt solution AMB CSA < Balanced salt solution PHMB < Balanced salt solution PHMB CSA < Balanced salt solution VCZ < Balanced salt solution VCZ CSA VCZ CSA AMB VCZ CSA VCZ VCZ CSA PHMB CSA PHMB AMB CSA AMB AMB CSA AMB VCZ CSA AMB CSA VCZ CSA CSA PHMB VCZ VCZ CSA PHMB CSA VCZ PHMB CSA AMB PHMB PHMB CSA AMB CSA VCZ CSA PHMB CSA VCZ AMB AMB CSA PHMB CSA PHMB AMB CSA PHMB CSA VCZ PHMB CSA CSA AMB CSA The mean end change in disease score between groups was compared using an ANOVA in which all pairwise comparisons between the eight groups were performed with Student s t-test. Significant differences are highlighted in bold.
6 7314 Rebong et al. IOVS, September 2011, Vol. 52, No. 10 FIGURE 5. All mice treated with CSA developed localized alopecia. genera with regard to gene targets as well as phenotypes attributed to calcineurin signaling have been identified. 31 Whether these differences can account for the two genera s different responses to calcineurin inhibitors is a topic that should be studied further. The additive as opposed to synergistic effects between FK506 and PHMB, AMB, or VCZ may reflect the different target sites for the drugs. Caspofungin inhibits the activity of 1,3- -Dglucan synthase, an enzyme critical for fungal cell wall synthesis. 28 AMB and VCZ, meanwhile, inhibit fungal cell membrane synthesis by interfering with ergosterol. The synergistic activity of calcineurin inhibitors with caspofungin and their additive activity with AMB and VCZ may be explained by the possibility that the calcineurin pathway plays a role in cell wall synthesis of Aspergillus species. Incidentally, although the antifungal activity of PHMB is not as well understood, its additive effect with calcineurin inhibitors supports the idea that PHMB acts at the level of the fungal cell membrane as opposed to the cell wall. Although the calculated FICI values did not meet the criteria for synergy, the observed morphologic changes clearly showed that FK506 enhanced the ability of PHMB, AMB, and VCZ to inhibit Aspergillus growth in vitro. Our in vitro studies indicate that calcineurin inhibitors like FK506 can have a role in improving the antifungal treatment of Aspergillus keratitis. Our in vivo studies showed little statistical significance when comparing noncontrol treatment groups, probably because of the low sample size. A smaller number of animals was desirable for this study, as it allowed us to establish and evaluate a novel mouse model of Aspergillus keratitis in addition to testing the effects of different drug combinations. Previous models of Aspergillus keratitis used rabbits, whose larger corneas make experimentation easier. 32,33 A mouse model of Aspergillus keratitis was created by Zhong et al., 34 who used a more complicated procedure similar to epikeratophakia compared with our method involving corneal de-epithelialization. Our studies showed that a procedure involving scratching of the cornea, as opposed to a more technically complicated procedure similar to epikeratophakia, can lead to successful infection of over 65% of inoculated mice. 34 This mouse model provides a more practical and economical option which can be used in future research on Aspergillus keratitis. We elected to use the calcineurin inhibitor CSA in our in vivo experiments rather than using FK506, as we did in our in vitro experiments. We initially chose FK506 for the in vitro experiments because it has been shown to be superior to CSA in its traditional role as an immunosuppressant after organ transplantation. 35 We then chose CSA for the in vivo experiments, because CSA is already commercially available and used to treat other ocular diseases such as dry eye syndrome. Although FK506 and CSA act on the same pathway by inhibiting calcineurin phosphatase, they bind to different members of the immunophilin family FK506 to FKBP12 and CSA to cyclophilin which, in cases of organ transplantation, leads to different risk and benefit profiles. 35 Whether these differences translate to the calcineurin pathway in fungi and whether these differences are significant are questions that have yet to be answered. If FK506 and CSA in fact behave differently in Aspergillus, it would help explain the discrepancy between our results. Key differences between in vitro studies and in vivo studies using calcineurin inhibitors may stem from the fact that calcineurin inhibitors in vivo not only exhibit an antifungal effect against Aspergillus but may also exert immunosuppressive effects on the host. During in vivo experiments, since calcineurin inhibitors are traditionally used as immunosuppressant agents, they may limit the host s ability to combat infection. Alternatively, calcineurin inhibitors may help suppress the host s inflammatory response, which at times can cause as much or more damage to the cornea than does the infection. To better define this issue, the balance between the antifungal and immunosuppressive effects of calcineurin inhibitors in host species requires further investigation. Another issue to consider with regard to our in vivo studies is that the preparation of the CSA ophthalmic solutions may have influenced their ability to be delivered effectively to the site of infection. Compared to the balanced salt solution, VCZ, AMB, and PHMB ophthalmic solutions, the CSA ophthalmic solution was more viscous due to being prepared in corn oil. CSA was more difficult to administer, not only because the viscous solution was difficult to apply but also because the animals more vigorously wiped it off after application. The alopecia resulting from CSA administration may be due to this vigorous wiping rather than or in addition to the properties of the drug itself. A viscous substance like CSA may be better applied and therefore absorbed across a larger surface area, like the human cornea, as opposed to the smaller corneas of our study animals. Considering alternative preparations for CSA may improve drug administration to and penetration of the cornea in future experiments. Future in vivo studies are needed to assess the effects of using calcineurin inhibitors to enhance the antifungal treatment of Aspergillus keratitis. If proven effective, the use of calcineurin inhibitors in conjunction with current antifungal therapies may lower the concentrations needed for the individual drugs to exert their desired effects. Using calcineurin inhibitors to enhance the treatment of Aspergillus keratitis would help avoid potential side effects at higher doses of the individual drugs and would increase the effectiveness of current treatment regimens against Aspergillus keratitis. Perhaps more importantly, the use of calcineurin inhibitors may help in avoiding the problem of growing fungal resistance when individual drugs are used alone. References 1. Klotz SA, Penn CC, Negvesky GJ, Butrus SI. Fungal and parasitic infections of the eye. Clin Microbiol Rev. 2000;13: Thomas PA. Current perspectives on ophthalmic mycoses. Clin Microbiol Rev. 2003;16:
7 IOVS, September 2011, Vol. 52, No. 10 Novel Treatments for Aspergillus Keratitis Basak SK, Basak S, Mohanta A, Bhowmick A. Epidemiological and microbiological diagnosis of suppurative keratitis in Gangetic West Bengal, eastern India. Indian J Ophthalmol. 2005;53: Bharathi MJ, Ramakrishnan R, Vasu S, Palaniappan R. Aetiological diagnosis of microbial keratitis in South India: a study of 1618 cases. Indian J Med Microbiol. 2002;20: Hagan M, Wright E, Newman M, Dolin P, Johnson G. Causes of suppurative keratitis in Ghana. Br J Ophthalmol. 1995;79: Leck AK, Thomas PA, Hagan M, et al. Aetiology of suppurative corneal ulcers in Ghana and south India, and epidemiology of fungal keratitis. Br J Ophthalmol. 2002;86: Srinivasan M. Fungal keratitis. Curr Opin Ophthalmol. 2004;15: Thomas PA. Fungal infections of the cornea. Eye (Lond). 2003;17: Gallis HA, Drew RH, Pickard WW. Amphotericin B: 30 years of clinical experience. Rev Infect Dis. 1990;12: Hariprasad SM, Mieler WF, Lin TK, Sponsel WE, Graybill JR. Voriconazole in the treatment of fungal eye infections: a review of current literature. Br J Ophthalmol. 2008;92: Wood TO, Tuberville AW, Monnett R. Keratomycosis and amphotericin B. Trans Am Ophthalmol Soc. 1985;83: Kaur IP, Rana C, Singh H. Development of effective ocular preparations of antifungal agents. J Ocul Pharmacol Ther. 2008;24: Mehta H, Mehta HB, Garg P, Kodial H. Voriconazole for the treatment of refractory Aspergillus fumigatus keratitis. Indian J Ophthalmol. 2008;56: Jones A, Muhtaseb M. Use of voriconazole in fungal keratitis. J Cataract Refract Surg. 2008;34: Jhanji V, Sharma N, Mannan R, Titiyal JS, Vajpayee RB. Management of tunnel fungal infection with voriconazole. J Cataract Refract Surg. 2007;33: Snelders E, van der Lee HA, Kuijpers J, et al. Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanism. PLoS Med. 2008;5:e Bellete B, Raberin H, Morel J, Flori P, Hafid J, Manhsung RT. Acquired resistance to voriconazole and itraconazole in a patient with pulmonary aspergilloma. Med Mycol. 2010;48: Beernaert LA, Pasmans F, Van Waeyenberghe L, et al. Avian Aspergillus fumigatus strains resistant to both itraconazole and voriconazole. Antimicrob Agents Chemother. 2009;53: Messick CR, Pendland SL, Moshirfar M, et al. In-vitro activity of polyhexamethylene biguanide (PHMB) against fungal isolates associated with infective keratitis. J Antimicrob Chemother. 1999;44: Fiscella RG, Moshifar M, Messick CR, Pendland SL, Chandler JW, Viana M. Polyhexamethylene biguanide (PHMB) in the treatment of experimental Fusarium keratomycosis. Cornea. 1997;16: Panda A, Ahuja R, Biswas NR, Satpathy G, Khokhar S. Role of 0.02% polyhexamethylene biguanide and 1% povidone iodine in experimental Aspergillus keratitis. Cornea. 2003;22: Clipstone NA, Crabtree GR. Identification of calcineurin as a key signalling enzyme in T-lymphocyte activation. Nature. 1992;357: Fortwendel JR, Juvvadi PR, Pinchai N, et al. Differential effects of inhibiting chitin and 1,3-{beta}-D-glucan synthesis in ras and calcineurin mutants of Aspergillus fumigatus. Antimicrob Agents Chemother. 2009;53: Steinbach WJ, Schell WA, Blankenship JR, Onyewu C, Heitman J, Perfect JR. In vitro interactions between antifungals and immunosuppressants against Aspergillus fumigatus. Antimicrob Agents Chemother. 2004;48: Steinbach WJ, Cramer RA Jr, Perfect BZ, et al. Calcineurin controls growth, morphology, and pathogenicity in Aspergillus fumigatus. Eukaryot Cell. 2006;5: Pinchai N, Perfect BZ, Juvvadi PR, et al. Aspergillus fumigatus calcipressin CbpA is involved in hyphal growth and calcium homeostasis. Eukaryot Cell. 2009;8: Onyewu C, Afshari NA, Heitman J. Calcineurin promotes infection of the cornea by Candida albicans and can be targeted to enhance fluconazole therapy. Antimicrob Agents Chemother. 2006;50: Kontoyiannis DP, Lewis RE, Osherov N, Albert ND, May GS. Combination of caspofungin with inhibitors of the calcineurin pathway attenuates growth in vitro in Aspergillus species. J Antimicrob Chemother. 2003;51: Clinical and Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi; approved standard. Document M38-A. Clinical and Laboratory Standards Institute, Wayne, PA; Afeltra J, Dannaoui E, Meis JF, Rodriguez-Tudela JL, Verweij PE. In vitro synergistic interaction between amphotericin B and pentamidine against Scedosporium prolificans. Antimicrob Agents Chemother. 2002;46: Steinbach WJ, Reedy JL, Cramer RA Jr, Perfect JR, Heitman J. Harnessing calcineurin as a novel anti-infective agent against invasive fungal infections. Nat Rev Microbiol. 2007;5: Garcia ML, Herreras JM, Dios E, Argueso P, Almaraz A. Evaluation of lectin staining in the diagnosis of fungal keratitis in an experimental rabbit model. Mol Vis. 2002;8: Dong X, Shi W, Zeng Q, Xie L. Roles of adherence and matrix metalloproteinases in growth patterns of fungal pathogens in cornea. Curr Eye Res. 2005;30: Zhong W, Yin H, Xie L. Expression and potential role of major inflammatory cytokines in experimental keratomycosis. Mol Vis. 2009;15: Haddad EM, McAlister VC, Renouf E, Malthaner R, Kjaer MS, Gluud LL. Cyclosporin versus tacrolimus for liver transplanted patients. Cochrane Database Syst Rev. 2006:CD
In Vitro Interactions of Antifungal agents and Tacrolimus against Aspergillus Biofilms
AAC Accepted Manuscript Posted Online 24 August 2015 Antimicrob. Agents Chemother. doi:10.1128/aac.01510-15 Copyright 2015, American Society for Microbiology. All Rights Reserved. 1 In Vitro Interactions
More informationNewer Combination Therapies
Newer Combination Therapies William J. Steinbach, MD Associate Professor of Pediatrics, Molecular Genetics & Microbiology Pediatric Infectious Diseases Duke University Medical Center Combination Therapy
More informationMycotic Keratitis in Patients Attending a Tertiary Care Hospital
International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 6 Number 10 (20) pp. 1665-1670 Journal homepage: http://www.ijcmas.com Original Research Article https://doi.org/10.20546/ijcmas.20.610.201
More informationNo Evidence As Yet. Georg Maschmeyer. Dept. of Hematology, Oncology & Palliative Care Klinikum Ernst von Bergmann Potsdam, Germany
Is Combined Antifungal Therapy More Efficient than Single Agent Therapy? No Evidence As Yet www.ichs.org Georg Maschmeyer Dept. of Hematology, Oncology & Palliative Care Klinikum Ernst von Bergmann Potsdam,
More informationAntifungal Activity of Voriconazole on Local Isolates: an In-vitro Study
Original Article Philippine Journal of OPHTHALMOLOGY Antifungal Activity of Voriconazole on Local Isolates: an In-vitro Study Karina Q. De Sagun-Bella, MD, 1 Archimedes Lee D. Agahan, MD, 1 Leo DP. Cubillan,
More informationNON TRADITIONAL MANAGEMENT OF FUNGAL KERATITIS
NON TRADITIONAL MANAGEMENT OF FUNGAL KERATITIS MOHAMED SAAD,MD PROF. OF OPHTHALMOLOGY ASSIUT UNIVERSITY HOSPITAL FINANCIAL DISCLOSURE: No financial interest. 1 Fungal keratitis is a sight-threatening condition
More informationANTIFUNGAL AGENTS. Alison Clode, DVM, DACVO. Port City Veterinary Referral Hospital Portsmouth, New Hampshire
ANTIFUNGAL AGENTS Alison Clode, DVM, DACVO Port City Veterinary Referral Hospital Portsmouth, New Hampshire New England Equine Medical and Surgical Center Dover, New Hampshire Overview Fungal organisms
More informationIn Vitro Comparison of Efficacy of Natamycin and Silver Nitrate against Ocular Fungi ACCEPTED
AAC Accepts, published online ahead of print on 12 January 2009 Antimicrob. Agents Chemother. doi:10.1128/aac.00697-08 Copyright 2009, American Society for Microbiology and/or the Listed Authors/Institutions.
More informationClinical Decision making in Infectious Keratitis
Clinical Decision making in Infectious Stephen D. McLeod, MD Theresa M. and Wayne M. Caygill, MD Distinguished Professor and Chair Department of Ophthalmology Francis I. Proctor Foundation University of
More informationIdentification of Fungal Species in Proved Cases of Fungal Corneal Ulcer
www.jmscr.igmpublication.org Impact Factor 3.79 ISSN (e)-2347-176x Identification of Fungal Species in Proved Cases of Fungal Corneal Ulcer Authors Madhusudhan C.N 1, Tanushree V 2, H.T.Venkategowda 3,
More informationVoriconazole. Voriconazole VRCZ ITCZ
7 7 8 7 8 fluconazole itraconazole in vitro in vivo Candida spp. C. glabrata C. krusei Cryptococcus neoformans in vitro Aspergillus spp. in vitro in vivo Aspergillus fumigatus Candida albicans C. krusei
More informationAUSTRALIAN ANTIFUNGAL SUSCEPTIBILITY DATA : PART 2 THE MOULDS ASPERGILLUS, SCEDOSPORIUM AND FUSARIUM.
AUSTRALIAN ANTIFUNGAL SUSCEPTIBILITY DATA 00-0: PART THE MOULDS ASPERGILLUS, SCEDOSPORIUM AND FUSARIUM. AUSTRALIAN Sarah Kidd, Rose Handke and ANTIFUNGAL David Ellis SUSCEPTIBILITY DATA 00-00 David SA
More informationCURRENT AND NEWER ANTI-FUNGAL THERAPIES- MECHANISMS, INDICATIONS, LIMITATIONS AND PROBLEMS. Dr AMIT RAODEO DM SEMINAR
CURRENT AND NEWER ANTI-FUNGAL THERAPIES- MECHANISMS, INDICATIONS, LIMITATIONS AND PROBLEMS Dr AMIT RAODEO DM SEMINAR Introduction The incidence of invasive fungal infections in critically ill intensive
More informationAntifungal Agents. Polyenes Azoles Allyl and Benzyl Amines Other antifungals
OPTO 6434 General Pharmacology Antifungal Agents Dr. Alison McDermott Room 254 HBSB, Phone 713-743 1974 Email amcdermott@optometry.uh.edu Fall 2015 Reading: Chapter 50 Brody s Human Pharmacology by Wecker
More informationLamellar Keratoplasty for the Treatment of Fungal Keratitis
Cornea 21(1): 33 37, 2002. 2002 Lippincott Williams & Wilkins, Inc., Philadelphia Lamellar Keratoplasty for the Treatment of Fungal Keratitis Lixin Xie, M.D., Weiyun Shi, M.D., Zhaosheng Liu, M.D., and
More informationIntroduction. Study of fungi called mycology.
Fungi Introduction Study of fungi called mycology. Some fungi are beneficial: ex a) Important in production of some foods, ex: cheeses, bread. b) Important in production of some antibiotics, ex: penicillin
More informationINCIDENCE OF CURVULARIA ORGANISM IN MYCOTIC CORNEAL ULCER K. Anjaneyulu 1, Balla Vidya Sagar 2
INCIDENCE OF CURVULARIA ORGANISM IN MYCOTIC CORNEAL ULCER K. Anjaneyulu 1, Balla Vidya Sagar 2 HOW TO CITE THIS ARTICLE: K. Anjaneyulu, Balla Vidya Sagar. Incidence of Curvularia Organism in Mycotic Corneal
More informationAn Update in the Management of Candidiasis
An Update in the Management of Candidiasis Daniel B. Chastain, Pharm.D., AAHIVP Infectious Diseases Pharmacy Specialist Phoebe Putney Memorial Hospital Adjunct Clinical Assistant Professor UGA College
More informationCigna Drug and Biologic Coverage Policy
Cigna Drug and Biologic Coverage Policy Subject Voriconazole Effective Date... 3/15/2018 Next Review Date... 3/15/2019 Coverage Policy Number... 4004 Table of Contents Coverage Policy... 1 General Background...
More informationA Clinical Microbiological Study of Corneal Ulcer Patients at Western Gujarat, India
A Clinical Microbiological Study of Corneal Ulcer Patients at Western Gujarat, India Rajesh Somabhai Katara 1, Nilesh Dhanjibhai Patel 2, and Mala Sinha 3 1 Department of Microbiology, B. J. Medical College,
More informationWHICH ANTIFUNGAL AGENT IS THE CHOICE FOR SUSPECTED FUNGAL INFECTIONS?
WHICH ANTIFUNGAL AGENT IS THE CHOICE FOR SUSPECTED FUNGAL INFECTIONS? Assoc. Prof. Dr. Serkan SENER Acibadem University Medical School Department of Emergency Medicine, Istanbul Acibadem Ankara Hospital,
More informationAntifungal Pharmacotherapy
Interpreting Antifungal Susceptibility Testing: Science or Smoke and Mirrors A. W. F O T H E R G I L L, M A, M B A U N I V E R S I T Y O F T E X A S H E A L T H S C I E N C E C E N T E R S A N A N T O
More informationFungal (Aspergillus and Candida) infections in Cystic fibrosis
Fungal (Aspergillus and Candida) infections in Cystic fibrosis Malena Cohen-Cymberknoh, MD CF Center Hadassah-Hebrew University Medical Center Jerusalem, Israel Israeli Annual CF Conference, Herzlyia,
More informationAntifungal Resistance in Asia: Mechanisms, Epidemiology, and Consequences
5th MMTN Conference 5-6 November 2016 Bangkok, Thailand 10:20-10:45, 6 Nov, 2016 Antifungal Resistance in Asia: Mechanisms, Epidemiology, and Consequences Yee-Chun Chen, M.D., PhD. Department of Medicine,
More informationDivision of Infectious Diseases, Department of Medicine, Wayne State University, Detroit, MI, USA
ORIGINAL ARTICLE 10.1111/j.1469-0691.2004.00996.x In-vitro activity of nikkomycin Z alone and in combination with polyenes, triazoles or echinocandins against Aspergillus fumigatus L. T. Ganesan, E. K.
More informationAntifungal drugs Dr. Raz Muhammed
Antifungal drugs 13. 12. 2018 Dr. Raz Muhammed 2. Flucytosine (5-FC) Is fungistatic Is a synthetic pyrimidine antimetabolite Is often used in combination with amphotericin B in the treatment of systemic
More informationAntifungal Pharmacodynamics A Strategy to Optimize Efficacy
Antifungal Pharmacodynamics A Strategy to Optimize Efficacy David Andes, MD Associate Professor, Department of Medicine Division of Infectious Diseases Medical Microbiology and Immunology University of
More informationSCY-078 ECMM Symposium Cologne, Germany October 2017
A New Path for Antifungal Treatments SCY-078 ECMM Symposium Cologne, Germany October 2017 David Angulo, M.D. Chief Medical Officer SCYNEXIS at a Glance Company created in 2000 Spin-off of Sanofi, initially
More informationESCMID Online Lecture Library. by author
The antibacterial experience: indications for clinical use of antimicrobial combinations To prevent the emergence of resistant organisms (tuberculosis) To treat polymicrobial infections (abdominal complicated
More informationISHAM Symposium: S33: Ocular aspects of Fungal Infections Friday, 8 May 2015, ; MR101/102 Level 1
ISHAM Symposium: S33: Ocular aspects of Fungal Infections Friday, 8 May 2015, 14.15 15.45; MR101/102 Level 1 Chairs: Ariya Chindamporn, TH and Phillip A Thomas, IN 14:15-14:35 AGENDA Clinical overview
More informationPrevalence of Oculomycosis in a Tertiary Care Centre
AJMS Al Ameen J Med Sci (2 011 )4 (4 ):3 3 4-3 3 8 (A US National Library of Medicine enlisted journal) I S S N 0 9 7 4-1 1 4 3 C O D E N : A A J M B G ORIGI NAL ARTICLE Prevalence of Oculomycosis in a
More informationUpdated Guidelines for Management of Candidiasis. Vidya Sankar, DMD, MHS April 6, 2017
Updated Guidelines for Management of Candidiasis Vidya Sankar, DMD, MHS April 6, 2017 Statement of Disclosure I have no actual or potential conflict of interest in relation to this presentation Outline
More informationVRCZ VRCZ VRCZ μg/ml
June 2016 THE JAPANESE JOURNAL OF ANTIBIOTICS 69 3 143 19 6 1, 2 1, 2 2 1 1 1 2 1 1 2 2016 4 6 VRCZ VRCZ 4 2 1 68 VRCZ 4 VRCZ VRCZ 2 81 VRCZVRCZ VRCZ 0.09 μg/ml 3 67 VRCZ VRCZ 4 3.79 μg/ml 4 68 VRCZ 42
More informationReceived 18 December 2008/Returned for modification 9 February 2009/Accepted 9 April 2009
JOURNAL OF CLINICAL MICROBIOLOGY, June 2009, p. 1942 1946 Vol. 47, No. 6 0095-1137/09/$08.00 0 doi:10.1128/jcm.02434-08 Copyright 2009, American Society for Microbiology. All Rights Reserved. Activity
More informationEfficacy of a Novel Echinocandin, CD101, in a Mouse Model of Azole-Resistant Disseminated Candidiasis
Efficacy of a Novel Echinocandin, CD0, in a Mouse Model of Azole-Resistant Disseminated Candidiasis L. Miesel, K-Y Lin, J. C. Chien, M. L. Hsieh, V. Ong, and K. Bartizal Eurofins Panlabs, Taipei, Taiwan
More informationLABORATORY SCIENCES. Antimicrobial Susceptibility of Fusarium, Aspergillus, and Other Filamentous Fungi Isolated From Keratitis
LABORATORY SCIENCES Antimicrobial Susceptibility of Fusarium, Aspergillus, and Other Filamentous Fungi Isolated From Keratitis Prajna Lalitha, MD; Brett L. Shapiro, BA; Muthiah Srinivasan, MD; Namperumalsamy
More informationSpectrum of Fungal Keratitis in North China
Spectrum of Fungal Keratitis in North China Lixin Xie, MD, 1 Wenxian Zhong, MD, 1,2 Weiyun Shi, MD, 1 Shiying Sun, MD 1 Purpose: To report the epidemiological features, laboratory findings, and treatment
More informationInternational Journal of Pharma and Bio Sciences
Research Article Microbiology International Journal of Pharma and Bio Sciences ISSN 0975-6299 INFECTIVE KERATITIS - PREDISPOSING FACTORS, CLINICAL AND MICROBIOLOGICAL ANALYSIS WITH ANTIBIOTIC SUSCEPTIBILITY
More informationAntifungal Susceptibility Testing
Infect Dis Clin N Am 20 (2006) 699 709 Antifungal Susceptibility Testing Annette W. Fothergill, MA, MBA, MT(ASCP), CLS(NCA) a, Michael G. Rinaldi, PhD a,b, Deanna A. Sutton, PhD, MT, SM(ASCP), SM, RM(NRM)
More informationClinical study to identify causative organism in microbial keratitis, their sensitivity pattern and treatment outcome.
IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-issn: 2279-0853, p-issn: 2279-0861. Volume 10, Issue 3 (Sep.- Oct. 2013), PP 27-31 Clinical study to identify causative organism in microbial keratitis,
More informationCombination Treatment of Invasive Fungal Infections
CLINICAL MICROBIOLOGY REVIEWS, Jan. 2005, p. 163 194 Vol. 18, No. 1 0893-8512/05/$08.00 0 doi:10.1128/cmr.18.1.163 194.2005 Copyright 2005, American Society for Microbiology. All Rights Reserved. Combination
More informationCD101: A Novel Echinocandin
CD101: A Novel Echinocandin Taylor Sandison, MD MPH Chief Medical Officer TIMM Belgrade, Serbia October 8, 2017 1 Disclosures Dr. Sandison is an employee of and stockholder in Cidara Therapeutics 2 Cidara
More informationGeorg Maschmeyer. Dept. of Hematology, Oncology & Palliative Care Klinikum Ernst von Bergmann Potsdam, Germany.
www.ichs.org Georg Maschmeyer Dept. of Hematology, Oncology & Palliative Care Klinikum Ernst von Bergmann Potsdam, Germany gmaschmeyer@klinikumevb.de www.dghoinfektionen.de 519 A. fumigatus isolates: Itraconazole
More informationThe incidence of invasive fungal infections
AN EPIDEMIOLOGIC UPDATE ON INVASIVE FUNGAL INFECTIONS * Michael A. Pfaller, MD ABSTRACT *Based on a presentation given by Dr Pfaller at a symposium held in conjunction with the 43rd Interscience Conference
More informationCommon Etiological Agents Causing Keratitis: A Study from a Tertiary Care Hospital in South India
International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 6 Number 7 (2017) pp. 1625-1633 Journal homepage: http://www.ijcmas.com Original Research Article https://doi.org/10.20546/ijcmas.2017.607.196
More informationFungi are eukaryotic With rigid cell walls composed largely of chitin rather than peptidoglycan (a characteristic component of most bacterial cell
Antifungal Drugs Fungal infections (Mycoses) Often chronic in nature. Mycotic infections may be superficial and involve only the skin (cutaneous mycoses extending into the epidermis) Others may penetrate
More informationColeophoma empetri FR901379, Fig. 1, ,,, 1,3- -D-glucan. . C. albicans A. fumigatus. Dixon plot C. albicans A. fumigatus 1,3- -D-glucan
Jpn. J. Med. Mycol. Vol. 46, 217222, 2005 ISSN 09164804,,,. echinocandin, pneumocandin. FR901379,., 1,3--D-glucan,,,., in vitro.,.,,. 2002,., 3,. Key words: micafungin, echinocandin, 1,3--D- 1,3--D-glucan
More informationTopical 5% Natamycin With Oral Ketoconazole in Filamentous Fungal Keratitis: A Randomized Controlled Trial
ORIGINAL CLINICAL STUDY With Oral in Filamentous Fungal Keratitis: A Randomized Controlled Trial Revathi Rajaraman, MS,* Parameshwar Bhat, MS,* Vikram Vaidee, DNB,* Sowmyalatha Maskibail, MS,* Anita Raghavan,
More informationCORNEAL CONDITIONS CORNEAL TRANSPLANTATION
GENERAL INFORMATION CORNEAL CONDITIONS CORNEAL TRANSPLANTATION WHAT ARE CORNEAL CONDITIONS? The cornea is the clear outer layer of the eye. Shaped like a dome, it helps to protect the eye from foreign
More informationActivity of Posaconazole Combined with Amphotericin B against Aspergillus flavus Infection in Mice: Comparative Studies in Two Laboratories
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Mar. 2004, p. 758 764 Vol. 48, No. 3 0066-4804/04/$08.00 0 DOI: 10.1128/AAC.48.3.758 764.2004 Copyright 2004, American Society for Microbiology. All Rights Reserved.
More informationManagement Strategies For Invasive Mycoses: An MD Anderson Perspective
Management Strategies For Invasive Mycoses: An MD Anderson Perspective Dimitrios P. Kontoyiannis, MD, ScD, FACP, FIDSA Professor of Medicine Director of Mycology Research Program M. D. Anderson Cancer
More informationM Rezanur Rahman, Gordon J Johnson, Rabiul Husain, Shahe A Howlader, Darwin C Minassian
Br J Ophthalmol 1998;82:919 925 919 Institute of Ophthalmology, Department of Preventive Ophthalmology, University College London, Bath Street, London, EC1V 9EL M R Rahman G J Johnson D C Minassian Eye
More informationClinical relevance of resistance in Aspergillus. David W. Denning University Hospital of South Manchester [Wythenshawe Hospital]
Clinical relevance of resistance in Aspergillus David W. Denning University Hospital of South Manchester [Wythenshawe Hospital] The University of Manchester Steps to establishing clinical validity of resistance/susceptibility
More informationAntifungal resistance mechanisms in pathogenic fungi
Antifungal resistance mechanisms in pathogenic fungi Shivaprakash M Rudramurthy Additional Professor, Mycology Division Center of Advanced Research in Medical Mycology, National Culture Collection of Pathogenic
More informationOriginal Article. Fungal keratitis in Melbourne INTRODUCTION ABSTRACT METHODS
Original Article Clinical and Experimental Ophthalmology 2007; 35: 124 130 doi:10.1111/j.1442-9071.2006.01405.x Fungal keratitis in Melbourne Prashant Bhartiya FRCS, 1,2 Mark Daniell FRANZCO, 1,2 Marios
More informationFactors influencing the Aspergillus fumigatus survival into the host mediated by the calcineurin pathway
Factors influencing the Aspergillus fumigatus survival into the host mediated by the calcineurin pathway Gustavo H. Goldman Universidade de São Paulo, Brazil Calcineurin is a calmodulin/ca +2 dependent
More informationFungal Infection in the ICU: Current Controversies
Fungal Infection in the ICU: Current Controversies Andrew F. Shorr, MD, MPH, FCCP, FACP Washington Hospital Center Georgetown University, Washington, DC Disclosures I have served as a consultant to, researcher/investigator
More informationUse of Antifungal Drugs in the Year 2006"
Use of Antifungal Drugs in the Year 2006" Jose G. Montoya, MD Associate Professor of Medicine Associate Chief for Clinical Affairs Division of Infectious Diseases Stanford University School of Medicine
More informationUpdate zu EUCAST 2012 Cornelia Lass-Flörl
Update zu EUCAST 2012 Cornelia Lass-Flörl Frühjahrstagung 2012 Paul-Ehrlich-Gesellschaft Sektion Antimykotische Chemotherapie Bonn, 4./5. Mai 2012 Agenda 1. Breakpoints 2. Rationale documents and technical
More informationANTIMYCOTIC DRUGS Modes of Action
ANTIMYCOTIC DRUGS Modes of Action Prapasarakul Nuvee, D.V.M., Ph.D. Department of Veterinary Microbiology, Faculty of Veterinary Science, Chulalongkorn University 1 What drugs act as antifungal agents?
More informationProphylaxis versus Diagnostics-driven approaches to treatment of Invasive fungal diseases. Y.L. Kwong Department of Medicine University of Hong Kong
Prophylaxis versus Diagnostics-driven approaches to treatment of Invasive fungal diseases Y.L. Kwong Department of Medicine University of Hong Kong Pathogenic yeast Candida Cryptococcus Trichosporon Pathogenic
More informationAntifungal Potential of Disulfiram
Jpn. J. Med. Mycol. Vol. 48, 109 113, 2007 ISSN 0916 4804 Short Report Antifungal Potential of Disulfiram Seema Khan 1, Smita Singhal 1, Tarun Mathur 1, Dilip J. Upadhyay 1, Ashok Rattan 2 1 Department
More informationDepartment of Pediatric Hematology/Oncology, University Children s Hospital Tübingen, Hoppe-Seyler-Strß 1, Tübingen, Germany 2
Case Reports in Transplantation Volume 2012, Article ID 672923, 4 pages doi:10.1155/2012/672923 Case Report Eradication of Pulmonary Aspergillosis in an Adolescent Patient Undergoing Three Allogeneic Stem
More informationMINIREVIEWS. Stress, Drugs, and Evolution: the Role of Cellular Signaling in Fungal Drug Resistance
EUKARYOTIC CELL, May 2008, p. 747 764 Vol. 7, No. 5 1535-9778/08/$08.00 0 doi:10.1128/ec.00041-08 Copyright 2008, American Society for Microbiology. All Rights Reserved. MINIREVIEWS Stress, Drugs, and
More informationon November 3, 2018 by guest
JOURNAL OF CLINICAL MICROBIOLOGY, June 2007, p. 1811 1820 Vol. 45, No. 6 0095-1137/07/$08.00 0 doi:10.1128/jcm.00134-07 Copyright 2007, American Society for Microbiology. All Rights Reserved. Multicenter
More informationSensitivity of Candida albicans isolates to caspofungin comparison of microdilution method and E-test procedure
Basic research Sensitivity of Candida albicans isolates to caspofungin comparison of microdilution method and E-test procedure Anna Serefko, Anna Malm Department of Pharmaceutical Microbiology, Medical
More informationAcanthameba Keratitis
Acanthameba Keratitis CHARALAMBOS S. SIGANOS, MD, PHD ASSOC. PROFESSOR OF OPHTHALMOLOGY UNIVERSITY OF CRETE DEPARTMENT OF OPHTHALMOLOGY HERAKLION UNIVERSITY HOSPITAL CRETE GREECE I declare no conflict
More informationThe Role of Ultrasonographic Biomicroscopy in the management of a patient with presumed Dematiaceous Mycotic Keratitis
ISPUB.COM The Internet Journal of Ophthalmology and Visual Science Volume 6 Number 2 The Role of Ultrasonographic Biomicroscopy in the management of a patient with presumed Dematiaceous Mycotic Keratitis
More informationResistance epidemiology
ECMM/EFISG symposium: Multidrug resistance in fungi? A formidable foe Resistance epidemiology Ana Alastruey Izquierdo Mycology Reference Lab Spain Instituto de Salud Carlos III Disclousure I have received
More informationFungal Infection Pre-Infusion Data
Fungal Infection Pre-Infusion Data Registry Use Only Sequence Number: Date Received: CIBMTR Center Number: Event date: / / CIBMTR Form 2046 revision 5 (page 1 of 5). Last Updated May, 2018. Infection Episode
More informationGAFFI Fact Sheet. Keratitis refers to inflammation (usually an infection) of the normally transparent DARKER AREAS AND
Fungal Keratitis GAFFI Fact Sheet GLOBAL ACTION FUND FOR FUNGAL INFECTIONS Keratitis refers to inflammation (usually an infection) of the normally transparent DARKER AREAS AND cornea of the eye, which
More informationnumber Done by Corrected by Doctor د.حامد الزعبي
number Fungi#1 Done by نرجس الس ماك Corrected by مهدي الشعراوي Doctor د.حامد الزعبي Introduction to Mycology -Terms: -Medical Mycology: The study of mycosis and their etiological agents -Mycosis: Disease
More informationSpectrum of Mycotic corneal ulcers in Mid Western peripheral region of Terrain belt of Nepal and Indo-Nepal Border
Nepal Journal of Medical Sciences Original Article Spectrum of Mycotic corneal ulcers in Mid Western peripheral region of Terrain belt of Nepal and Indo-Nepal Border Bastola P, 1* Mishra A, 2 Chaudhary
More informationCombination Antifungal Therapy for Invasive Pulmonary Aspergillosis in a Heart Transplant Recipient
case report Combination Antifungal Therapy for Invasive Pulmonary Aspergillosis in a Heart Transplant Recipient Andres Beiras-Fernandez, 1 * Amir K. Bigdeli, 1 * Thomas Nickel, 2 Sebastian Michel, 1 Peter
More informationMicafungin and Candida spp. Rationale for the EUCAST clinical breakpoints. Version February 2013
Micafungin and Candida spp. Rationale for the EUCAST clinical breakpoints. Version 1.0 5 February 2013 Foreword EUCAST The European Committee on Antimicrobial Susceptibility Testing (EUCAST) is organised
More informationVIRULENCE FACTORS AND SUSCEPTIBILITY OF CANDIDA SPP. CAUSATIVE AGENTS OF NEONATAL INFECTIONS
VIRULENCE FACTORS AND SUSCEPTIBILITY OF CANDIDA SPP. CAUSATIVE AGENTS OF NEONATAL INFECTIONS Nikola Stojanović, Predrag Stojanović, Suzana Otašević, Valentina Arsić-Arsenijević What do we know? - Third
More informationAntifungal drug resistance mechanisms in pathogenic fungi: from bench to bedside
REVIEW 10.1111/1469-0691.12495 Antifungal drug resistance mechanisms in pathogenic fungi: from bench to bedside M. Cuenca-Estrella National Center for Microbiology, Instituto de Salud Carlos III, Madrid,
More informationTreatment of fungal keratitis by penetrating keratoplasty
1070 Shandong Eye Institute and Hospital, Qingdao 266071, PR China L Xie X Dong W Shi Correspondence to: Lixin Xie, MD, Shandong Eye Institute and Hospital, 5 Yanerdao Road, Qingdao 266071, PR China lixinxie@public.qd.sd.cn
More informationFungal infections in ICU. Tang Swee Fong Department of Paediatrics Universiti Kebangsaan Malaysia
Fungal infections in ICU Tang Swee Fong Department of Paediatrics Universiti Kebangsaan Malaysia Epidemiology of invasive fungal infections - US +300% Martin GS, et al. N Engl J Med 2003;348:1546-1554
More informationOptimizing antifungal dosing regimens. Joseph Meletiadis, PhD, FECMM Assistant Professor of Microbiology
ATHENA 2017 International Conference November 28 30, 2017 Optimizing antifungal dosing regimens Joseph Meletiadis, PhD, FECMM Assistant Professor of Microbiology Clinical Microbiology Laboratory, «Attikon»
More informationREAL-WORLD UTILIZATION PATTERNS OF CYCLOSPORINE OPHTHALMIC EMULSION 0.05% WITHIN MANAGED CARE
REAL-WORLD UTILIZATION PATTERNS OF CYCLOSPORINE OPHTHALMIC EMULSION 0.05% WITHIN MANAGED CARE Tina H Chiang 1, John G Walt 1, John P McMahon, Jr. 2, James E Mansfield, Jr. 2, Susan Simonyi 3 1 Allergan
More informationMANAGEMENT OF HOSPITAL-ACQUIRED FUNGAL INFECTIONS
MANAGEMENT OF HOSPITAL-ACQUIRED FUNGAL INFECTIONS Paul D. Holtom, MD Associate Professor of Medicine and Orthopaedics USC Keck School of Medicine Numbers of Cases of Sepsis in the United States, According
More informationAntifungal Update. Candida: In Vitro Antifungal Susceptibility Testing
Antifungal Update B. Joseph Guglielmo, Pharm.D. Professor and Chair Department of Clinical Pharmacy School of Pharmacy University of California San Francisco The patient spikes a new fever and 3/3 blood
More informationDALK IN DANGEROUS INFECTIONS
32 INTERNATIONAL CONGRESS of the HELLENIC SOCIETY OF INTRAOCULAR IMPLANT AND REFRACTIVE SURGERY CORNEA ROUND TABLE: STROMAL REPAIR DALK IN DANGEROUS INFECTIONS, MD Clinica Degli Occhi Sarnicola, Grosseto
More informationCLINICAL SCIENCES z. Aqueous and Vitreous Concentrations Following Topical Administration of 1% Voriconazole in Humans
CLINICAL SCIENCES z Aqueous and Vitreous Concentrations Following Topical Administration of 1% Voriconazole in Humans G. Atma Vemulakonda, MD; Seenu M. Hariprasad, MD; William F. Mieler, MD; Randall A.
More informationEpidemiological and microbiological profile of infective keratitis in Ahmedabad
Original Article Epidemiological and microbiological profile of infective keratitis in Ahmedabad Aarti Tewari, Nidhi Sood, Mahendra M Vegad, Dipak C Mehta Context: Study of patients attending tertiary
More informationINVELTYS (loteprednol etabonate ophthalmic suspension) 1%, for topical ophthalmic use Initial U.S. Approval: 1998
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use INVELTYS safely and effectively. See full prescribing information for INVELTYS. INVELTYS (loteprednol
More informationTable 1. Antifungal Breakpoints for Candida. 2,3. Agent S SDD or I R. Fluconazole < 8.0 mg/ml mg/ml. > 64 mg/ml.
AUSTRALIAN ANTIFUNGAL SUSCEPTIBILITY DATA 2008-2011 Part 1: The Yeasts In this article, an update of recent changes to the CLSI antifungal standards for susceptibility testing of yeasts is presented. We
More informationSYNERGISTIC ACTIVITIES OF TWO PROPOLIS WITH AMPHOTERICIN B AGAINST SOME AZOLE-RESISTANT CANDIDA STRAINS. PART II
SYNERGISTIC ACTIVITIES OF TWO PROPOLIS WITH AMPHOTERICIN B AGAINST SOME AZOLE-RESISTANT CANDIDA STRAINS. PART II DURAN NIZAMI 1, MUZ MUSTAFA 2, DURAN GULAY GULBOL 3, OZER BURCIN 1, ONLEN YUSUF 4 1 Mustafa
More informationAssessment of Keratitis Damage in an Age Dependent Mouse Model Using Analytical Software
Assessment of Keratitis Damage in an Age Dependent Mouse Model Using Analytical Software Quincy C. Moore III, PhD, 1 Emmanuel B. Olorunyomi, 1 Miles E. DuBose, 2 and Cleveland O. Lane Jr, PhD 1 1 Prairie
More informationH erpes simplex virus infection of the
Herpes simplex keratitis An experimental study Samuel J. Kimura, Victor Diaz-Bonnet, and Masao Okumoto The incidence of complicated herpes simplex keratitis appears to have increased and the important
More informationSolid organ transplant patients
M.6 Meet-the-expert sessions Solid organ transplant patients Martin Iversen, Denmark José M. Aguado, Spain Copenhagen, Sunday 13 October 2013 Conflict of interest disclosure In the past 5 years, J.M.A.
More informationHow Can We Prevent Invasive Fungal Disease?
How Can We Prevent Invasive Fungal Disease? Chris Kibbler Professor of Medical Microbiology University College London And Royal Free Hospital, London, UK Invasive Aspergillosis 2 - Acquisition Preventive
More informationTherapeutic Effects of 0.1% Tacrolimus Eye Drops for Refractory Vernal Keratoconjunctivitis
IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-issn: 2279-0853, p-issn: 2279-0861.Volume 15, Issue 3 Ver. VI (Mar. 2016), PP 44-48 www.iosrjournals.org Therapeutic Effects of 0.1% Tacrolimus
More informationMicrobial Keratitis in East Africa: why are the outcomes so poor?
Europe PMC Funders Group Author Manuscript Published in final edited form as: Ophthalmic Epidemiol. 2011 August ; 18(4): 158 163. doi:10.3109/09286586.2011.595041. Microbial Keratitis in East Africa: why
More informationAntifungal susceptibility testing: Which method and when?
Antifungal susceptibility testing: Which method and when? Maiken Cavling Arendrup mad@ssi.dk SSI & Juan Luis Rodriguez Tudela jlrtudela@isciii.es ISCIII Agenda Summary of current standards and selected
More informationAPX001 A novel broad spectrum antifungal agent in development for the treatment of invasive fungal infections
APX001 A novel broad spectrum antifungal agent in development for the treatment of invasive fungal infections TIMM, Belgrade, Serbia October, 2017 New antifungal drugs in the pipeline S15 Dr. Michael Hodges
More information